ICS 2022: Compliance With Uresta (Cure) Study; A 12 Month Follow-Up Of 40 Women

(UroToday.com) This was a UK prospective study of the compliance at 12 months of the use of a vaginal device, the Uresta bladder support, for management of stress urinary incontinence (SUI). Interestingly, study recruitment was through advertisements on social media, running clubs, and gyms. Outcomes were assessed using the PUQ, ICIQ-FLUTS, UDI-6, IIQ-7, QUID, and PGI-I questionnaires.

Forty-six women were recruited with an average age of 42 yrs, BMI of 24, and parity of 2.3. The most common activities were running (48%) and CrossFit (22%). Compliance was 90% at 12 months (n=40, 6 withdrew after 2 weeks). Uresta insertion was 'okay', 'easy' or 'very easy' for 86% of participants, and removal was 'okay', 'easy' or 'very easy' for 75% of participants, Leakage was improved (n=13), greatly improved (n=12) or stopped (n=5) for 83% of participants, 75% were ‘much better’ or ‘very much better’ on the PGI-I scale, and 94% would recommend Uresta to a friend. There were no adverse events. The authors conclude that the Uresta bladder support is a safe, effective, user-friendly management option for women with SUI during exercise with 90% compliance at 12 months.
uresta diagram
Presented by: Patrick Campbell, Kingsbridge Private Hospital, Belfast, United Kingdom

Written by: Diane Newman, DNP, CRNP, FAAN, BCB-PMD, Urologic Nurse Practitioner, Adjunct Professor of Urology in Surgery, Senior Research Investigator, Perelman School of Medicine, University of Pennsylvania during the International Continence Society Annual Meeting, September 7-10, 2022, Vienna, Austria. 


  1. Lovatsis D, Best C, Diamond P. Short-term Uresta efficacy (SURE) study: a randomized controlled trial of the Uresta continence device. Int Urogynecol J 2016; Jul 20. [Epub ahead of print] DOI:10.1007/s00192-016-3090-9